Huntington's Disease Progression: A Population Modeling Approach to Characterization Using Clinical Rating Scales
- 16 May 2020
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 60 (8) , 1051-1060
Abstract
Development of effective therapeutics that slow Huntington's disease progression is a research priority that requires an understanding of natural disease progression. We applied a population‐modeling approach to describe the progression of 2 routinely used rating scales — the total motor score and the total functional capacity score. Models were fitted to data from research participants aged ≥ 18 years with Huntington's disease stage I or II at study entry (total functional capacity score ≥ 7), from a controlled clinical trial (CARE‐HD) and 2 observational studies (COHORT and Registry). A logistic model without shape factors was selected as the base model based on placebo data from CARE‐HD and validated using data from the CARE‐HD active‐treatment arms. Albeit with a smaller progression rate constant than was found in CARE‐HD, the proposed models provided reasonable predictions for both rating scales in the pooled data from COHORT and Registry and were considered suitable for use in clinical trial simulations. Results also showed that disease burden score (a product of age and expanded CAG length) is a significant covariate on both the progression rate constant and the baseline score in the total motor score model. These findings suggest that total motor score and total functional capacity progress fastest near their half‐maximal score, implying that the efficiency of clinical trials evaluating disease‐modifying therapeutics for Huntington's disease could be enhanced by enrolling patients with faster disease progression or evaluating treatment effect near their half‐maximal score, provided that the evaluated therapy is expected to be efficacious at this disease stage.Keywords
Funding Information
- CHDI Foundation
This publication has 21 references indexed in Scilit:
- Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY)Journal of Neurology, Neurosurgery & Psychiatry, 2014
- Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational dataThe Lancet Neurology, 2013
- An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging InitiativeThe Journal of Clinical Pharmacology, 2012
- Characterization of a Large Group of Individuals with Huntington Disease and Their Relatives Enrolled in the COHORT StudyPLOS ONE, 2012
- Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational dataThe Lancet Neurology, 2012
- Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysisThe Lancet Neurology, 2011
- Quantitative Disease, Drug, and Trial ModelsAnnual Review of Pharmacology and Toxicology, 2009
- Modeling the time-course of Alzheimer dementiaCurrent Psychiatry Reports, 2001
- Unified Huntington's disease rating scale: Reliability and consistencyMovement Disorders, 1996
- Huntington's disease in venezuela: 7 years of follow‐up on symptomatic and asymptomatic individualsMovement Disorders, 1990